Fig. 5From: Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways a Prohibitin expression in malignant papillary serous cystadenocarcinoma. (IHC; ×40). b Prohibitin expression in malignant mucinous cystadenocacinoma. (IHC; ×40). c Prohibitin expression in malignant endometrioid carcinoma (IHC; ×40). d Prohibitin expression in poorly differentiated carcinoma (IHC; ×40)Back to article page